Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?

促黄体激素 睾酮(贴片) 内分泌学 促性腺细胞 内科学 激素 医学
作者
Tom Pickles,Jeremy Hamm,William Morris,William E. Schreiber,Scott Tyldesley
出处
期刊:BJUI [Wiley]
卷期号:110 (11b) 被引量:54
标识
DOI:10.1111/j.1464-410x.2012.11190.x
摘要

Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Previous reports, with small numbers of patients, have described the problem of incomplete testosterone suppression (>1.1 or 1.7 nmol/L) with LHRH agonists. Various predisposing factors have been suggested: different drug agents and patient factors such as age, pretreatment testosterone levels and weight. Such incomplete testosterone suppression has been shown in one small report to be associated with increased PSA failure rates and in another report in those with metastases, with worse survival. This study used testosterone assays that are more accurate at low levels than those used in most previous reports in a large dataset of 2196 men, and confirmed incomplete testosterone suppression (breakthrough) rates >1.7 nmol/L of 3.4% and >1.1 nmol/L of 6.6%. We showed that younger age was strongly associated with the risk of breakthrough, with a minor effect of increasing body mass index. Repeated breakthroughs were more common (16%) in those who had already had one breakthrough. Interim measures of cancer control (PSA kinetics during LHRH therapy) were inferior in those with a breakthrough, and those with breakthroughs between 1.1 and 1.7 nmol/L had worse long‐term biochemical control rates. OBJECTIVES To describe breakthrough rates above castrate levels of testosterone, in a population‐based series of men undergoing adjuvant luteinizing hormone‐releasing hormone (LHRH) agonist therapy with curative radiation therapy. To explore the predisposing factors for such breakthroughs and their impact on subsequent outcomes. PATIENTS AND METHODS All men treated for prostate cancer between 1998 and 2007 with curative radiation in the province of British Columbia, Canada were potentially eligible ( n = 11 752). Of these, 2196 fulfilled the eligibility criteria. Serial testosterone measurements were obtained during continuous LHRH therapy. Breakthrough rates >1.1 nmol/L and >1.7 nmol/L were calculated for each LHRH injection and for each patient course. Predisposing factors were identified, and early surrogates of oncological outcome (neoadjuvant nadir and post‐treatment nadir) were determined. RESULTS The risk of a breakthrough >1.1 nmol/L was 6.6%, and >1.7 nmol/L was 3.4% per patient course and 5.4% and 2.2% per LHRH injection (inclusive ranges). Repeated breakthroughs occurred in 16% of patients. Younger men were more liable to breakthroughs ( P < 0.001). Early PSA kinetic surrogates of cancer control were inferior in those with breakthroughs. Neither overall biochemical non‐evidence of disease (bNED) nor survival were compromised, although subgroup analysis showed inferior 5‐year bNED in those with breakthroughs of 1.1–1.7 nmol/L vs those without (58% vs 73%, respectively; P = 0.048). CONCLUSIONS Breakthroughs with LHRH agonists occur occasionally per injection, but occur commonly per patient course of treatment, and adversely affect early surrogate measures of outcome. The monitoring of testosterone levels during therapy is therefore advised.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
9秒前
李爱国应助大橙子采纳,获得10
10秒前
magictoo发布了新的文献求助30
16秒前
18秒前
yang完成签到,获得积分10
18秒前
Minicoper发布了新的文献求助10
19秒前
快乐丸子完成签到,获得积分10
20秒前
简单而复杂完成签到,获得积分10
20秒前
大橙子发布了新的文献求助10
24秒前
张牧之完成签到 ,获得积分10
26秒前
冷冷暴力完成签到,获得积分10
28秒前
YYY完成签到,获得积分10
28秒前
28秒前
gujian完成签到 ,获得积分10
31秒前
帅气的秘密完成签到 ,获得积分10
32秒前
自然函发布了新的文献求助10
36秒前
冰冰双双完成签到,获得积分10
36秒前
开心夏旋完成签到 ,获得积分0
38秒前
我要读博士完成签到 ,获得积分10
41秒前
活泼的大船完成签到,获得积分10
41秒前
AFF完成签到,获得积分10
42秒前
43秒前
无私小小完成签到,获得积分10
44秒前
随心所欲完成签到 ,获得积分10
45秒前
润润轩轩完成签到 ,获得积分10
46秒前
CodeCraft应助大橙子采纳,获得10
46秒前
ZR完成签到,获得积分10
47秒前
magictoo完成签到,获得积分10
47秒前
陈昊发布了新的文献求助10
48秒前
zhangliangfu完成签到 ,获得积分10
48秒前
金石为开完成签到,获得积分10
48秒前
王QQ完成签到 ,获得积分10
50秒前
唐唐完成签到 ,获得积分10
54秒前
最棒哒完成签到 ,获得积分10
54秒前
鸣鸣完成签到,获得积分10
55秒前
123321完成签到 ,获得积分10
56秒前
卓若之完成签到 ,获得积分10
57秒前
苯二氮卓完成签到,获得积分10
58秒前
温暖完成签到 ,获得积分10
1分钟前
mojomars完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022